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Abstract
As breast cancer survival increases, cardiotoxicity associated with chemotherapeutic regimens
such as anthracyclines and trastuzumab becomes a more significant issue. Assessment of the left
ventricular (LV) ejection fraction fails to detect subtle alterations in LV function. The objective of
this study was to evaluate whether more sensitive echocardiographic measurements and
biomarkers could predict future cardiac dysfunction in chemotherapy-treated patients. Forty-three
patients diagnosed with breast cancer who received anthracyclines and trastuzumab therapy
underwent echocardiography and blood sampling at 3 time points (baseline and 3 and 6 months
during the course of chemotherapy). The LV ejection fraction; peak systolic myocardial
longitudinal, radial, and circumferential strain; echocardiographic markers of diastolic function;
N-terminal pro–B-type natriuretic peptide; and high-sensitivity cardiac troponin I were measured.
Nine patients (21%) developed cardiotoxicity (1 at 3 months and 8 at 6 months) as defined by the
Cardiac Review and Evaluation Committee reviewing trastuzumab. A decrease in longitudinal
strain from baseline to 3 months and detectable high-sensitivity cardiac troponin I at 3 months
were independent predictors of the development of cardiotoxicity at 6 months. The LV ejection
fraction, parameters of diastolic function, and N-terminal pro–B-type natriuretic peptide did not
predict cardiotoxicity. In conclusion, cardiac troponin plasma concentrations and longitudinal
strain predict the development of cardiotoxicity in patients treated with anthracyclines and
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trastuzumab. The 2 parameters may be useful to detect chemotherapy-treated patients who may
benefit from alternative therapies, potentially decreasing the incidence of cardiotoxicity and its
associated morbidity and mortality.
The overall objective of this study was to assess whether early echocardiographic
measurements of myocardial deformation and biomarkers (high-sensitivity troponin I
[hsTnI] and N-terminal pro–B-type natriuretic peptide [NT-proBNP]) could predict the
development of chemotherapy-induced cardiotoxicity in patients treated with anthracyclines
and trastuzumab. Cardiotoxicity was defined according to recent guidelines (Cardiac Review
and Evaluation Committee of trastuzumab-associated cardiotoxicity) as a reduction of the
left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or
an asymptomatic reduction of the LVEF of ≥10% to <55%.1
Methods
Patients >18 years of age diagnosed with HER-2-overexpressing breast cancer and either
scheduled to receive treatment including anthracyclines and trastuzumab or scheduled to
receive trastuzumab after previous anthracycline treatment were eligible. Patients with
LVEFs <50% were excluded.
Patients were enrolled at 4 institutions. All patients signed informed consent forms, which
were approved by the institutional review board of the participating institutions.
Patients were studied before chemotherapy (except 10 patients who had previously been
treated with anthracyclines) and at 3 and 6 months of treatment, using questionnaires,
echocardiography, and blood samples.
Transthoracic echocardiography was performed using the Vivid 7 or E9 (GE Healthcare,
Milwaukee, Wisconsin). The same ultrasound machine was used to acquire all
echocardiograms in each patient. All echocardiograms were analyzed in a core laboratory.
The LVEF was calculated from the apical 4- and 2-chamber views using a modified
Simpson’s biplane method2 by a single observer (M.S.-C.). All other measurements were
acquired by a single observer (H.S.) blinded to the results of the LVEF measurements. The 2
readers were blinded to the treatment that patients were receiving and to the time points
during the study. Mitral E and A waves and annular velocities were measured. Left atrial
volume was calculated from the apical 4- and 2-chamber views using the area-length
method. To measure myocardial strain, 2-dimensional grayscale images were obtained in the
parasternal short-axis view at the midpapillary level and the apical 4- and 2-chamber views.
The timing of aortic valve closure was obtained using pulsed-wave Doppler traces. Peak
systolic radial and circumferential strain were measured by averaging the peak systolic
strain values in all 6 segments of the parasternal short-axis view (EchoPAC; GE
Healthcare). In 5 patients for radial strain and 11 patients for circumferential strain, >2 of 6
segments could not be reproducibly analyzed at 1 time point. This was especially the case
when the sonographer was unable to obtain a perfectly rounded parasternal short-axis view.
The values of radial and circumferential strain were excluded for these patients.
Furthermore, particularly in patients with left-sided breast cancer, the apex was difficult to
visualize (inability to obtain standard apical views, chest pain, scar tissue, expanders). We
estimate that in 60% to 70% of the patients, the apex was not analyzable at all time points.
Hence, global peak systolic longitudinal strain was calculated by averaging the values of
peak systolic strain in the basal and midwall segments of the 4- and 2-chamber views.
Longitudinal, radial, and circumferential strain values were averaged over 3 cardiac cycles.
The intraobserver variability for longitudinal strain reported as the mean error ± SD of 10
measurements was −0.14 ± 1.1% in absolute values (−0.58 ± 6.5% in percentages) and the
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interobserver variability as 0.5 ± 1.5 % in absolute values (2.7 ± 7.9% in percentages). The
variabilities for radial strain were 2 ± 5% (2.5 ± 9.6%) and 2.2 ± 7.5% (4.4 ± 14.4%),
respectively. The intraobserver variability for circumferential strain was 0.53 ± 2.82% in
absolute values (2 ± 13% in percentages), and the interobserver variability was 3.3 ± 3.5%
in absolute values (19 ± 21% in percentages).
NT-proBNP and troponin I were measured using the Dimension Vista 500 Intelligent
Laboratory System (Siemens Healthcare Diagnostics, Deerfield, Illinois), using a 1-step,
homogenous, sandwich chemiluminescent immunoassay based on LOCI technology
(Siemens Healthcare Diagnostics, Deerfield, Illinois). The limit of detection of NT-proBNP
assay is 0.8 pg/ml. Typical within-laboratory imprecision for the assay is <3% coefficient of
variation at NT-proBNP concentration from 120 to 5,000 pg/ml. The highest value of NT-
proBNP reported in healthy subjects aged <75 years is 125 pg/ml. The lower limit of
detection of the troponin assay is 0.015 µg/L, and the 10% coefficient of variation is <0.04
µg/L. All values of NT-proBNP >125 pg/ml and of troponin >0.015 µg/L were considered
elevated.
Data are expressed as mean ± SD. All statistical analyses were performed using the JMP
statistical package (SAS Institute Inc., Cary, North Carolina). Assuming a baseline peak
systolic longitudinal strain in healthy patients of 19 ± 5%3 and a rate of left ventricular
dysfunction of 20%,4 the analysis of 45 patients was expected to allow us to detect a
decrease of 14% in longitudinal strain in the left ventricular dysfunction group with power
of 80% and a 5% level of significance. Parameters of interest were compared at baseline and
at 3 and 6 months in the population using a 1-way analysis of variance for repeated
measures. Possible predictors of cardiotoxicity were tested using univariate nominal logistic
regression. The primary hypothesis was to test the echocardiographic markers of systolic
function and the biomarkers. Echocardiographic markers of diastolic function were also
tested because they have been reported to decrease in patients treated with anthracyclines. A
multiple nominal logistic regression model including longitudinal strain and troponin levels
at 3 months was then applied to the univariate predictors. Because radial strain could not be
reliably obtained in all patients, it was excluded from the model. A p value <0.05 was
defined as significant.
Results
Forty-five eligible consecutive women were prospectively enrolled in the study. One woman
withdrew from the study and 1 was withdrawn because of negative HER-2 status on a
second analysis. Therefore, a total of 43 women participated in the study. Ten women
received anthracyclines before entering the study. The median delay time between the
anthracycline treatment and the initial study time point was 3.5 months (range 2 to 144).
There was no difference in the baseline or changes in the clinical parameters,
echocardiographic measurements, and biomarker levels between naive and previously
treated women. All women were therefore analyzed together. Baseline characteristics of the
patients are listed in Table 1.
At baseline, the LVEF and peak systolic longitudinal and radial strain were within the
normal reported range of values3 (Table 2). When the group was analyzed as a whole, the
LVEF decreased by an average of 8%. This decrease was significant at 6 but not at 3
months. Longitudinal strain decreased by 11%; this decrease was significant 3 months after
the start of the study period. The decrease in longitudinal strain observed at 3 months was
detected in the midwall (p = 0.008) and the lateral (p = 0.01) and anterior (p = 0.01)
segments. Circumferential strain decreased by a mean of 15% at 6 months and was already
decreased at 3 months. In contrast, radial strain did not decrease at 3 months when all
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women were studied. No change in hsTnI or NT-proBNP was noted in the course of the
study.
Nine patients (21%) met the criteria for cardiotoxicity. Cardiotoxicity was detected at the 3-
month time point in 1 patient (immediately after anthracyclines), whereas 8 other patients
developed cardiotoxicity at the 6-month time point. There were no differences in any of the
echocardiographic or blood markers at baseline between patients who did or did not develop
cardiotoxicity. Importantly, the change of the LVEF from baseline to 3 months was not
predictive of later cardiotoxicity (p = 0.19; Table 3). This was also true when change in the
LVEF was considered a discrete change, and patients were separated by those who did or
did not have decreases in the LVEF of >5%. The individual changes in the LVEF and
longitudinal strain are shown in Figure 1 in patients who did or did not develop
cardiotoxicity.
In contrast, decreases in longitudinal strain and radial strain and elevated hsTnI at 3 months
were predictive of patients who developed cardiotoxicity at 6 months (Table 3).
Furthermore, the number of abnormal segments at 3 months (defined either as segments in
which longitudinal strain decreased by ≥10% between baseline and 3 months of treatment or
by absolute segmental values of strain less than the mean – 2 SD value of the same segment
at baseline in the entire cohort) was lower in patients who did not develop cardiotoxicity
than in patients who did. The number of abnormal segments at 3 months was predictive of
cardiotoxicity (p <0.01 for both definitions). The decrease in circumferential strain was not
predictive of later cardiotoxicity. Neither the change in NT-proBNP between baseline and 3
months nor an NT-proBNP level higher than normal limits at 3 months predicted
cardiotoxicity. None of the echocardiographic indexes of diastolic function at 3 months or
their change between 0 and 3 months was predictive of cardiotoxicity at 6 months.
By multiple logistic regression analysis, elevated hsTnI at 3 months (p <0.02) and a decrease
in longitudinal strain between baseline and 3 months (p <0.02) remained independent
predictors of later cardiotoxicity.
Longitudinal strain decreased by >10% between 0 and 3 months in 14 patients (32%). HsTnI
was elevated at 3 months in 12 patients (28%). The sensitivity, specificity, and positive and
negative predictive values of hsTnI elevation and/or of a decrease of >10% in longitudinal
strain are reported in Table 4.
Discussion
In the present study, we report that in patients treated with a combination of anthracyclines
and trastuzumab, an early decrease in myocardial strain or elevation in plasma troponin as
detected with a high-sensitivity assay predicts the later occurrence of cardiotoxicity.
Subsequent cardiotoxicity is not clearly predicted by early changes in the LVEF or NT-
proBNP level.
Patients enrolled in our study experienced decreases in the LVEF of similar magnitude as
those reported previously in patients treated with anthracyclines and trastuzumab.4–6 Peak
systolic radial, longitudinal, and circumferential strain decreased before any LVEF decrease.
Similarly, in 13 children and in 16 women treated with anthracyclines, investigators reported
decreases in peak systolic longitudinal and radial strain during the treatment.7,8 In contrast,
echocardiograms obtained before and after trastuzumab therapy did not reveal a decrease in
myocardial strain.9 Although we reported that in a mouse model of anthracycline-induced
cardiotoxicity, myocardial strain rate predicted later decrease in the LVEF and subsequent
mortality,10 the value of an early measurement of myocardial strain in humans for the
prediction of later cardiotoxicity has not been reported.
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Several factors may explain the increased sensitivity of strain compared to the LVEF in the
detection of early cardiotoxicity found in our patients. As suggested by our findings, it is
conceivable that the chemotherapy-induced cardiotoxicity has a regional pattern; the
function of some myocardial segments may compensate for others, leading to a preserved
LVEF, at least in the early stages. Another possible contributing factor to the higher
sensitivity of strain compared to the LVEF may be variability. Strain measurement involves
the averaging of the automated measurement of multiple segments, whereas LVEF
assessment involves a tracing leading to 1 measurement. The variability (especially in the
longitudinal dimension) may therefore be lower for strain than for the LVEF, particularly in
patients with suboptimal images.
Using a high-sensitivity assay, we found that troponin I was elevated at 3 months of
treatment in 28% of patients, suggesting that myocardial damage is frequent in
chemotherapy-treated patients. Whereas Cardinale et al11 detected elevated troponin in 33%
of patients after high doses of anthracyclines, more recent studies report less frequent
troponin elevation and no value in predicting the decrease in LVEF after anthracyclines.12,13
In the present study, 1 sample obtained at 3 months of treatment was able to detect later
LVEF decrease in 6 of 9 patients. Reconciling the results of previous studies, it is necessary
to point out that the assay used in this study possesses an analytic precision that allows
resolution of very small elevations in troponin I.
Neither the baseline value nor the change in NT-proBNP between 0 and 3 months was
predictive of later decrease in the LVEF. Patients decreased their mitral annular velocities (E
′) throughout the treatment (p = 0.004). This decrease was not accompanied by a decrease in
the ratio of transmitral early peak velocity to early mitral annular velocity (E/E′) and may
reflect subtle diastolic abnormalities rather than changes in filling pressures. This decrease
was significant at the earliest time point (3 months) and is consistent with the early diastolic
abnormalities reported in earlier studies.14–16
The follow-up period of the patients was 6 months; longer periods of follow-up will be
necessary to determine whether the decrease of longitudinal strain or the increase in troponin
is predictive of later cardiac events. The estimated sensitivity and specificity should also
only be considered preliminary estimates considering the small number of patients.
The clinical implications of the present study are important. The reported findings
demonstrate that myocardial strain and troponin, 2 noninvasive, easily performed
measurements, recognize subtle myocardial alterations and predict later decrease in the
LVEF in patients receiving anthracyclines and trastuzumab. The negative predictive value of
the 2 tests allows the confident exclusion of cardiotoxicity detected by LVEF assessment 3
months later. Patients who do not have decreases of >10% in their peak systolic longitudinal
strain or elevated hsTnI levels have a 3% probability of decreases in their LVEFs 3 months
after the evaluation. In contrast, patients who either demonstrate decreases in longitudinal
strain or elevations in hsTnI have a ninefold increase in risk for cardiotoxicity at 6 months
compared to those with no changes in either of these markers. The presence of these
predictive markers does not mandate cessation of a potentially lifesaving anticancer therapy.
Rather, myocardial strain and hsTnI measurements may help target patients who could
benefit from closer cardiac monitoring, earlier initiation of cardioprotective medical therapy,
or less cardiotoxic novel tyrosine kinase inhibitors and anticancer drugs.
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Figure 1.
Individual changes in the LVEF (A) and longitudinal strain (B) in patients who did not
develop (left) and those who developed (right) cardiotoxicity.
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Table 1
Baseline clinical characteristics of patients treated with anthracyclines and trastuzumab who developed or did
not develop cardiotoxicity
Cardiotoxicity
Variable Yes
(n = 9)
No
(n = 34)
p
Value
Age (years) 47 ± 11 49 ± 10 0.94
Previous treatment with anthracyclines 2 (22%) 8 (23%) 1.00
Dose of anthracyclines 1.00
  Doxorubicin 240 mg/m2 9 (100%) 30 (88%)
  Epirubicin 300 mg/m2 0 (0%) 4 (12%)
Treatment with taxanes 9 (100%) 34 (100%) 1.00
Radiotherapy 2 (22%) 3 (9%) 0.28
Side of breast cancer 1.00
  Right 3 (33%) 14 (41%)
  Left 6 (67%) 19 (56%)
  Both 0 (0%) 1 (3%)
Cardiac risk factors
  Blood pressure ≥140/≥90 mm Hg 2 (22%) 10 (29%) 1.00
  Total cholesterol >200 mg/dl 0 (0%) 8 (23%) 0.66
  Diabetes mellitus 0 (0%) 1 (3%) 1.00
  Smoker 1 (11%) 5 (15%) 0.31
Cardiovascular therapy
  Angiotensin-converting enzyme inhibitors 1 (11%) 3 (9%) 0.19
  β blockers 0 (0%) 3 (9%) 1.00
Body mass index (kg/m2) 23 ± 12 26 ± 4 0.74
Systolic blood pressure (mm Hg) 120 ± 11 122 ± 18 0.98
Diastolic blood pressure (mm Hg) 75 ± 10 74 ± 9 0.19
Heart rate (beats/min) 71 ± 11 69 ± 9 0.38
Data are expressed as mean ± SD or as number (percentage).
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Table 2
Clinical, echocardiographic, and biomarker characteristics of 43 patients before and after treatment with
anthracyclines and trastuzumab
Variable Baseline 3 Months 6 Months p Value
(ANOVA)
Systolic blood pressure (mm Hg) 122 ± 17 116 ± 18 119 ± 15 0.07
Diastolic blood pressure (mm Hg) 74 ± 9 72 ± 10 72 ± 9 0.33
Heart rate (beats/min) 69 ± 10 72 ± 10 73 ± 11 0.10
LV end-diastolic volume (ml) 74 ± 13 74 ± 18 76 ± 8 0.58
LV end-systolic volume (ml) 26 ± 7 28 ± 9 33 ± 11 <0.0001
LVEF 0.65 ± 0.06 0.63 ± 0.06 0.59 ± 0.05 <0.0001
LV end-diastolic diameter (mm) 43 ± 4 43 ± 3 44 ± 4 0.16
Relative wall thickness 0.39 ± 0.07 0.37 ±0.06 0.37 ± 0.06 0.12
Longitudinal strain (%) 20.5 ± 2.2 19.3 ± 2.4* 18.4 ± 3 <0.0001
Radial strain (%) 55 ± 12 52 ± 12 46 ± 14 0.02
Circumferential strain (%) 18 ± 4 15 ± 4‡ 14 ± 3 0.001
Left atrial volume (ml) 32 ± 12 32 ± 9.5 32 ± 11.5 0.91
Mitral E-wave filling velocity (cm/s) 77 ± 17 75 ± 19 76 ± 18 0.36
Mitral A-wave filling velocity (cm/s) 67 ± 15 65 ± 15 64 ± 19 0.69
Mitral E-wave filling velocity/mitral A-wave filling velocity 1.2 ± 0.3 1.2 ± 0.3 1.3 ± 0.4 0.44
Peak early diastolic mitral annular velocity (cm/s) 12.5 ± 2.8 11.8 ± 3.1† 11 ± 2.5 0.004
Peak late diastolic mitral annular velocity (cm/s) 10 ± 3 10 ± 3 9 ± 2 0.11
Mitral E-wave filling velocity/peak early diastolic mitral annular velocity 6.7 ± 2 6.8 ± 2.6 7 ± 2.3 0.59
hsTnI (µg/L) 0.00 ± 0.01 0.04 ± 0.13 0.02 ± 0.07 0.09
NT-proBNP (pg/ml) 103 ± 73 98 ± 105 91 ± 114 0.12
Data are expressed as mean ± SD.
*p <0.001.
†p <0.02.
‡p = 0.001 versus baseline.
ANOVA = analysis of variance; LV = left ventricular.
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Table 4
Sensitivity, specificity, and positive and negative value of the predictors of cardiotoxicity
Predictor Sensitivity Specificity Positive Predictive
Value
Negative Predictive
Value
10% decrease in longitudinal strain 7/9 (78%) 27/34 (79%) 7/14 (50%) 27/29 (93%)
Elevated hsTnI at 3 months 6/9 (67%) 28/34 (82%) 6/12 (50%) 28/31 (90%)
10% decrease in longitudinal strain and elevated hsTnI at 3
months
5/9 (55%) 33/34 (97%) 5/6 (83%) 33/37 (89%)
10% decrease in longitudinal strain or elevated hsTnI at 3 months 8/9 (89%) 22/34 (65%) 8/20 (40%) 22/23 (97%)
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